[go: up one dir, main page]

ECSP10010473A - NEW DERIVATIVES OF CARBAZOL, INHIBITORS OF HSP90, COMPOSITIONS THAT CONTAIN THEM AND USE - Google Patents

NEW DERIVATIVES OF CARBAZOL, INHIBITORS OF HSP90, COMPOSITIONS THAT CONTAIN THEM AND USE

Info

Publication number
ECSP10010473A
ECSP10010473A EC2010010473A ECSP10010473A ECSP10010473A EC SP10010473 A ECSP10010473 A EC SP10010473A EC 2010010473 A EC2010010473 A EC 2010010473A EC SP10010473 A ECSP10010473 A EC SP10010473A EC SP10010473 A ECSP10010473 A EC SP10010473A
Authority
EC
Ecuador
Prior art keywords
alkyl
optionally substituted
hsp90
carbazol
inhibitors
Prior art date
Application number
EC2010010473A
Other languages
Spanish (es)
Inventor
Franck Halley
Jean-Marie Ruxer
Patrick Mailliet
Luc Bertin
Herve Minoux
Maria Mendez-Perez
Marcel Alasia
Victor Certal
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39930567&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP10010473(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of ECSP10010473A publication Critical patent/ECSP10010473A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

La invención se refiere a nuevos productos de fórmula (I): en los que Het representa un heterociclo opcionalmente sustituido por uno o varios radicales R1 o R'1, R se elige del grupo constituido por Fórmula (II) con R1 y/o R'1, elegidos entre: H, halógeno, CF3, nitro, ciano, alquilo, hidroxi, mercapto, amino, alquilamino, dialquilamino, alcoxi, fenilalcoxi, alquiltio, carboxi libre o esterificado por un radical: alquilo, carboxamida, CO-NH(alquilo), CON(alquilo)2, NH-CO-alquilo, sulfonamida, NH-SO2-alquilo, S(O)2-NHalquilo, S(O2)-N(alquilo)2; todos estos radicales opcionalmente sustituidos; W1, W2, W3 representan independientemente CH o N, X representa: O, S, NR2, C(O), S(O) o S(O)2; Z representa: H, Hal, -O-R2 o -NH-R2 donde R2 representa: H, alquilo, cicloalquilo o heterocicloalquilo opcionalmente sustituidos; estando estos productos en todas las formas isómeras y las sales, como medicamentos.The invention relates to new products of formula (I): in which Het represents a heterocycle optionally substituted by one or more radicals R1 or R'1, R is selected from the group consisting of Formula (II) with R1 and / or R '1, chosen from: H, halogen, CF3, nitro, cyano, alkyl, hydroxy, mercapto, amino, alkylamino, dialkylamino, alkoxy, phenylalkoxy, alkylthio, free or esterified carboxy by a radical: alkyl, carboxamide, CO-NH ( alkyl), CON (alkyl) 2, NH-CO-alkyl, sulfonamide, NH-SO2-alkyl, S (O) 2-NHalkyl, S (O2) -N (alkyl) 2; all these optionally substituted radicals; W1, W2, W3 independently represent CH or N, X represents: O, S, NR2, C (O), S (O) or S (O) 2; Z represents: H, Hal, -O-R2 or -NH-R2 where R2 represents: H, optionally substituted alkyl, cycloalkyl or heterocycloalkyl; these products being in all isomeric forms and salts, as medicines.

EC2010010473A 2008-03-14 2010-09-10 NEW DERIVATIVES OF CARBAZOL, INHIBITORS OF HSP90, COMPOSITIONS THAT CONTAIN THEM AND USE ECSP10010473A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0801394A FR2928645A1 (en) 2008-03-14 2008-03-14 NOVEL CARBAZOLE DERIVATIVES INHIBITORS OF HSP90, COMPOSITIONS CONTAINING SAME AND USE THEREOF

Publications (1)

Publication Number Publication Date
ECSP10010473A true ECSP10010473A (en) 2010-10-30

Family

ID=39930567

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010473A ECSP10010473A (en) 2008-03-14 2010-09-10 NEW DERIVATIVES OF CARBAZOL, INHIBITORS OF HSP90, COMPOSITIONS THAT CONTAIN THEM AND USE

Country Status (24)

Country Link
US (1) US8309721B2 (en)
EP (1) EP2265598A2 (en)
JP (1) JP5674483B2 (en)
KR (1) KR20100130603A (en)
CN (1) CN102026992A (en)
AR (1) AR070836A1 (en)
AU (1) AU2009232121A1 (en)
BR (1) BRPI0909731A2 (en)
CA (1) CA2718488A1 (en)
CL (1) CL2009000619A1 (en)
CO (1) CO6251295A2 (en)
CR (1) CR11653A (en)
DO (1) DOP2010000272A (en)
EA (1) EA201071078A1 (en)
EC (1) ECSP10010473A (en)
FR (1) FR2928645A1 (en)
IL (1) IL208059A0 (en)
MA (1) MA32206B1 (en)
MX (1) MX2010010018A (en)
NI (1) NI201000150A (en)
PE (1) PE20091673A1 (en)
TW (1) TW200938541A (en)
UY (1) UY31711A (en)
WO (1) WO2009122034A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011035416A1 (en) * 2009-09-25 2011-03-31 Aegera Therapeutics Inc. Hsp90 modulating compounds, compositions, methods and uses
TW201309672A (en) 2011-01-07 2013-03-01 Taiho Pharmaceutical Co Ltd Novel indole or indazole derivative or salt thereof
WO2012093708A1 (en) * 2011-01-07 2012-07-12 大鵬薬品工業株式会社 Novel bicyclic compound or salt thereof
JP5842630B2 (en) 2011-03-16 2016-01-13 株式会社リコー Carbazole derivatives and semiconductor nanocrystals
JP2014075556A (en) * 2012-10-05 2014-04-24 Idemitsu Kosan Co Ltd Organic electroluminescent element material and organic electroluminescent element using the same
CN104903308B (en) * 2013-01-10 2018-06-08 默克专利股份有限公司 Piperidyl carbazoles as antimalarial
EP3059225A4 (en) 2013-10-17 2017-09-06 Shionogi & Co., Ltd. Novel alkylene derivative
EP3077388A1 (en) 2013-12-05 2016-10-12 Pharmacyclics, LLC Inhibitors of bruton's tyrosine kinase
US20170158636A1 (en) * 2014-07-16 2017-06-08 Novogen Ltd. Functionalised and substituted carbazoles as anti-cancer agents
SG11201702464WA (en) * 2014-10-01 2017-04-27 Janssen Pharmaceuticals Inc Mono- or di-substituted indoles as dengue viral replication inhibitors
PH12017501272B1 (en) * 2015-01-16 2023-01-11 Janssen Pharmaceuticals Inc Indole derivatives as dengue viral replication inhibitors
BR112017022987A2 (en) * 2015-04-29 2018-07-24 Arena Pharm Inc 1-heteroaryl indoline-4-carboxamides as gpr52 modulators useful for treating or preventing related disorders
JOP20160086B1 (en) * 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
JOP20160198B1 (en) * 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc Single or di-substituted indole derivatives as inhibitors of viral replication of fennel fever
JO3633B1 (en) * 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development Single or binary substituted indole derivatives as inhibitors of viral replication of fennel fever
DE102016122122B4 (en) * 2015-11-18 2021-02-11 Cynora Gmbh Organic molecules, in particular for use in organic optoelectronic devices
US9966542B2 (en) * 2016-06-02 2018-05-08 E I Du Pont De Nemours And Company Electroactive materials
DE102017008073A1 (en) * 2017-08-28 2019-02-28 Henkel Ag & Co. Kgaa New anionic surfactants and detergents and cleaners containing them
CN111217741B (en) * 2019-03-01 2022-03-15 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） Fluorine-substituted monocarbazole derivatives, preparation method and application thereof
JP2025515506A (en) * 2022-04-28 2025-05-15 ダナトラス ファーマシューティカルズ カンパニー、リミテッド Tricyclic heterocyclic derivatives, compositions thereof and uses thereof
WO2024199444A1 (en) * 2023-03-31 2024-10-03 上海翊维康医药有限责任公司 Heteroaromatic ring compound, preparation method therefor, and use thereof
CN117229196A (en) * 2023-08-23 2023-12-15 贵州省茶叶研究所 Salicylaldehyde carbazole compound and application thereof
CN117159570B (en) * 2023-11-01 2024-01-23 云南中医药大学 Application of 6-acyloxymannose azide derivatives in combination with fluconazole in the preparation of drugs against drug-resistant Candida albicans
CN117486782A (en) * 2023-12-29 2024-02-02 中国医学科学院药用植物研究所 N-substituted carbazole derivative and preparation method and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1317926B1 (en) * 2000-11-03 2003-07-15 Sigma Tau Ind Farmaceuti TRICYCLIC DERIVATIVES OF INDOLE FOR ANTIANGIOGENIC ACTIVITY.
WO2006055760A1 (en) * 2004-11-18 2006-05-26 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
AU2006292429A1 (en) * 2005-09-16 2007-03-29 Serenex, Inc. Carbazole derivatives
US8405508B2 (en) 2006-08-09 2013-03-26 Emd Millipore Corporation Use of gamma hardened RFID tags in pharmaceutical devices

Also Published As

Publication number Publication date
WO2009122034A8 (en) 2010-08-19
TW200938541A (en) 2009-09-16
DOP2010000272A (en) 2010-10-15
JP5674483B2 (en) 2015-02-25
WO2009122034A3 (en) 2009-12-03
MA32206B1 (en) 2011-04-01
NI201000150A (en) 2011-03-29
KR20100130603A (en) 2010-12-13
EP2265598A2 (en) 2010-12-29
CL2009000619A1 (en) 2011-02-18
FR2928645A1 (en) 2009-09-18
JP2011513473A (en) 2011-04-28
CN102026992A (en) 2011-04-20
CA2718488A1 (en) 2009-10-08
PE20091673A1 (en) 2009-11-14
UY31711A (en) 2009-11-10
BRPI0909731A2 (en) 2019-03-06
US8309721B2 (en) 2012-11-13
US20110166169A1 (en) 2011-07-07
CO6251295A2 (en) 2011-02-21
MX2010010018A (en) 2010-12-15
AR070836A1 (en) 2010-05-05
IL208059A0 (en) 2010-12-30
CR11653A (en) 2010-11-22
AU2009232121A1 (en) 2009-10-08
EA201071078A1 (en) 2011-04-29
WO2009122034A2 (en) 2009-10-08

Similar Documents

Publication Publication Date Title
ECSP10010473A (en) NEW DERIVATIVES OF CARBAZOL, INHIBITORS OF HSP90, COMPOSITIONS THAT CONTAIN THEM AND USE
AR052866A1 (en) SUBSTITUTED MONOCICLIC PHENYL-METANONES
AR089774A1 (en) DERIVATIVES OF INDOLIZINE, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
CY1112102T1 (en) Substituted Pyramidodiazepine Uses As Suspensions PLK1
UY30105A1 (en) NEW SULFURED DERIVATIVES OF CYCLIC UREA, ITS PREPARATION AND ITS PHARMACEUTICAL USE AS INHIBITORS OF KINASES.
MX2013006847A (en) FUSIONED HETEROCICLIC COMPOUND AND ITS USE FOR PEST CONTROL.
AR088352A1 (en) ANTAGONISTS OF THE RECEIVER OF 2-PIRIDILOXI-4-NITRILE OREXINE
PE20060570A1 (en) QUINAZOLINE AND ISOQUINOLINE PIPERIDYL COMPOUNDS SUBSTITUTED AS PHOSPHODIESTERASE PDE-10 INHIBITORS
CY1112914T1 (en) Substituted Indolyl Alkyl Amine Derivatives as New Suspensions of Hastonine Disinfectants
AR076435A1 (en) COMPOUNDS OF REPLACED INDAZOLS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND PROCESSES TO OBTAIN THEMSELVES
AR074021A1 (en) FUSIONED HETEROCICLICAL COMPOUNDS AS IONIC CHANNEL MODULATORS
CY1116168T1 (en) TOY CCR3 HYPERCELLULATORS AND SALT SALTS
AR099913A1 (en) DERIVATIVES OF INDOLIZINE, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR091519A1 (en) TANQUIRASA PIRROLOPIRAZONA INHIBITORS
AR086590A1 (en) CYCLHEXANONE AND HERBICIDE COMPOUNDS THAT UNDERSTAND THEM
AR103742A1 (en) DERIVATIVES OF TRIFLUOROMETILPROPANAMIDA
AR082111A1 (en) FUROPIRIDINES OR CONDENSED TENOPIRIDINS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM USEFUL TO TREAT PSYCHOTIC AND CENTRAL NERVOUS SYSTEM DISORDERS, AND THE SAME PREPARATION METHOD
AR053340A1 (en) DERIVATIVES OF TRIFLUORMETILBENZAMIDA AND ITS THERAPEUTIC USES
CO6150147A2 (en) DERIVED FROM 5,6-BISARIL-2-PIRIDIN-CARBOXAMIDA ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS AS ANTAGONISTS OF UROTENSIN II RECEPTORS
MX2011009806A (en) Hsp90 inhibiting indazole derivatives, compositions containing same and use thereof.
CO6400223A2 (en) DERIVATIVES OF 6- (6-O-SUBSTITUTED-TRIAZOLOPIRIDAZINA-SULFANIL) BENZOTIAZOLES AND BENCIMIDAZOLS: PREPARATION, APPLICATION AS MEDICATIONS AND USE AS MET INHIBITORS
CO6160311A2 (en) NEW FLUORENE DERIVATIVES COMPOSITIONS CONTAINING AND USING AS INHIBITORS OF CHAPERONA HSP90 PROTEIN
BR112013016637A2 (en) process for the preparation of 3-alkylsulfinylbenzoyl derivatives
AR093801A1 (en) DERIVATIVES OF REPLACED 1,4-DITIINE AND ITS USE AS FUNGICIDES
CO6280537A2 (en) NEW DERIVATIVES OF PIRROLOINDOL INHIBITORS OF HSP90 COMPOSITIONS CONTAINING AND USING